DGAP-News: Quidel Corporation
LivLyme Foundation Founder Olivia Goodreau to Discuss Perils of Lyme Disease in Free Webinar Hosted by Industry-Leading
Quidel Corporation
2021-08-10 / 15:00
The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Olivia Goodreau, who founded the LivLyme Foundation at 12 years old and has since become a widely respected advocate
and national spokeswoman for Lyme disease prevention and treatment, will discuss her 'journey with Lyme' and the
importance of early testing as part of a webinar to be held Thursday, Aug. 19. The webinar is the latest in an ongoing
series sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing
rapid diagnostic health solutions.
______________________________________________________________________
Webinar Registration
The free online educational program will take place Aug. 19 at noon EDT. Registration is available now at https://
education.quidel.com/registration/2580/1/r/LD-1. You may attend the webinar by accessing the same link on or after Aug.
19 at noon EDT.
______________________________________________________________________
Now 16 years old, Goodreau founded the LivLyme Foundation in 2017 to help raise money for individuals who cannot afford
their Lyme medication or doctors' visits and to fund research to find a cure for Lyme and tick-borne diseases. She has
since awarded 54 grants to children and adults ages 2-21 along with four grants to top universities to fund tick-borne
disease research. Goodreau is also the inventor of TickTracker, the free global app that has over 50,000 users in
multiple languages worldwide. TickTracker was selected by the U.S. Department of Health and Human Services as the 'top
tech tool' that is solving global health problems, beating out Oracle and IBM, among others.
As part of the webinar, Goodreau will discuss her journey with Lyme, including when she became ill, the number of
physicians she visited, how she was diagnosed and her passion for the importance of early testing. She will also
discuss her work on the 'public stage,' having presented TickTracker at the White House and having met with countless
members of Congress, celebrities, scientists and governmental agencies to educate and spread awareness about tick-borne
diseases.
Goodreau's webinar presentation is particularly relevant today as Lyme disease is on the rise to record numbers
throughout the country and has the potential to affect as many as 476,000 citizens before the year is out. For accurate
and fast testing, more and more clinicians are turning to the Sofia(R) 2 Lyme FIA by Quidel. This revolutionary test
provides the patient and physician with indicative results within 15 minutes, as opposed to days, which has
historically been the norm (and during which time organisms can spread and become systemic). It can be performed in the
privacy of a doctor's office, local clinic or even by a nurse at a children's summer camp; and it is the only test that
can get results from a simple finger prick of blood.
Among those expected to attend the free Aug. 19 webinar are physicians; allied health professionals; health
researchers; and representatives of physician offices, laboratories, urgent care centers, patient advocacy associations
and others interested in the subject.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a
continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An
innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test
for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand
names, Sofia(R), Solana(R), Lyra(R), Triage(R) and QuickVue(R), Quidel's comprehensive product portfolio includes tests
for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect
COVID-19. With products made in America, Quidel's mission is to provide patients with immediate and frequent access to
highly accurate, affordable testing for the good of our families, our communities and the world. For more information
about Quidel, visit quidel.com.
Contact Details
Jim Yeager
+1 818-264-6812
jim@breakwhitelight.com
Company Website
http://Quidel.com
News Source: News Direct
-----------------------------------------------------------------------------------------------------------------------
2021-08-10 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
-----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Quidel Corporation
United States
EQS News ID: 1225381
End of News DGAP News Service
------------- 1225381 2021-08-10
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1225381&application_name=news
(END) Dow Jones Newswires
August 10, 2021 09:00 ET (13:00 GMT)
